Loading…
for educational and safety purposes
Adrafinil and Modafinil both come up in the same conversations; they overlap on Wakefulness. Adrafinil: Adrafinil (CRL-40028) is a prodrug of modafinil and one of the most accessible routes to clean, sustained wakefulness and focus. Modafinil: Modafinil is a prescription wakefulness-promoting drug, approved in the United States in 1998 for excessive sleepiness caused by narcolepsy, obstructive sleep apnea, and shift work disorder.
Adrafinil (CRL-40028) is a prodrug of modafinil and one of the most accessible routes to clean, sustained wakefulness and focus. Once converted by the liver into modafinil, it delivers the same eugeroic, alertness-promoting effect that made modafinil famous, without requiring a prescription in many countries. Marketed originally in Europe as Olmifon, it remains a favorite among those seeking long-lasting, jitter-light energy and mental stamina.
Modafinil is a prescription wakefulness-promoting drug, approved in the United States in 1998 for excessive sleepiness caused by narcolepsy, obstructive sleep apnea, and shift work disorder. It works mainly by blocking the dopamine transporter, the protein that clears dopamine out of the synapse; human brain imaging confirms it occupies roughly half of those transporters at ordinary doses, although it binds them far more weakly than classic stimulants do. The evidence that it reduces sleepiness in the three approved sleep disorders is strong and rests on large placebo-controlled trials, but the evidence that it improves thinking in healthy, well-rested people is much weaker; the best meta-analysis found only a small overall effect confined to one narrow memory task. It is a Schedule IV controlled substance in the United States, banned in competition by WADA, and carries warnings for rare but serious skin reactions and for making hormonal birth control less reliable.
both fingerprints on one instrument; where the marks line up the two compounds work the same lever, where a slot goes dark only one of them touches it. read straight from each entry's affinity table; nothing here is invented.
weakly inhibits
weak selective inhibitor
activates
raises
converts to
processed by
Downstream mediator of behavioural effect, not a binding site.
Indirect. Apparent occupancy changes because synaptic dopamine rises, not because modafinil binds the receptor.
Indirect circuit activation.
Required downstream circuit for arousal.
inhibits
Indirect circuit activation; not required for wake promotion.
No meaningful interaction demonstrated.
strengths are the entries' qualitative ratings (strong / moderate / weak); Ki and EC50 figures appear where an entry records them.
easiest to source: Modafinil is currently listed by more trusted vendors (2), so it's the simpler one to get hold of. for effects and safety, read each full entry; this is educational, not medical advice.